Not Yet Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06391164

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Sponsor: PHARMENTERPRISES LLC

Conditions Cystitis

Interventions Placebo XC243 25 mg XC243 50 mg XC243 75 mg

Updated 4 times since 2024 Last updated: Apr 25, 2024 Started: Apr 30, 2024 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystitis and is currently actively recruiting participants. PHARMENTERPRISES LLC leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PHARMENTERPRISES LLC

Data source: PHARMENTERPRISES LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia
• Saint Petersburg, Russia